CNNMoney.com
Companies Economy International Corrections Pre-market Trading After-hours Trading Winners/Losers/Actives Bonds Currencies Commodities World Markets Money Magazine Real Estate Taxes Jobs Ask the Expert Money 101 Autos Mutual Funds The Help Desk Loan Center Best Places to Live Ask the Expert Ultimate Guide to Retirement Retirement Calculators Best Funds Ask the Mole Best Places to Retire Big Tech Blog Techland Blog Sectors and Stocks Fortune 500 Techs Tech Talk 100 Best Places to Launch Ultimate Resource Guide Small Biz Makeovers FSB 100 Ask & Answer Fortune 500 Technology Investing Management C-Suite Rankings Main Create Portfolio Edit Portfolio Create Alerts Edit Alerts
More Galleries
Oakland: The other city by the bay This west coast port city has way more to offer than its reputation suggests. More
The barter business In a tough economy, more small business owners are conserving cash by bartering. The U.S. boasts some 500 barter exchanges - here's a sampling of established and reputable outfits. More
No power outlet? No problem Unplug your adventures with off-the-grid gadgets. More

Special Offer
4 of 36
BACK NEXT
4th place: Wirelessly zapping pain
4th place: Wirelessly zapping pain
Charles Lusk, Jordan Curnes, Will Rosellini, Joseph Picken (faculty advisor) and Ali Abbassi
Team name: MicroTransponder

School name: University of Texas Dallas, The School of Management

Team members: Will Rosellini, Jordan Curnes, Ali Abbassi, Charles Lusk

Concept: The founders of MicroTransponder believe they have found a way to eliminate the suffering of patients with chronic pain. Their product - RF-MEMS, or Radio Frequency Micro-Electromechanical Systems - sends wireless signals from a PDA or laptop that directs hair-thin devices injected near patient nerves to shut off pain receptors.

Currently, patients suffering with neuropathies - nerve function problems caused by disease, injury, infection or toxic substance exposure - lack reliable treatment. MicroTransponder's founders argue that the leading neuropathy medication is relatively ineffective, has negative side effects and is expensive. Traditional, wired neurostimulation devices that are surgically implanted also a number of limitations, including the size of the electrodes used and the reliability of batteries implanted in the body. The MicroTransponder is 100 times smaller than current devices, operates wirelessly, and does not require an internal battery.

Timeline: The firm hopes to have a prototype ready by 2009. -Shara Rutberg

NEXT: 5th place: Solar energy gets cheap

Last updated May 02 2008: 11:51 AM ET
© 2009 Cable News Network. A Time Warner Company. All Rights Reserved. Terms under which this service is provided to you. Privacy Policy
Copyright © 2009 BigCharts.com Inc. All rights reserved. Please see our Terms of Use.
MarketWatch, the MarketWatch logo, and BigCharts are registered trademarks of MarketWatch, Inc.
Intraday data provided by Interactive Data Real-Time Services and subject to the Terms of Use.
Intraday data is at least 20-minutes delayed. All times are ET.
Historical, current end-of-day data, and splits data provided by Interactive Data Pricing and Reference Data.
Fundamental data provided by Morningstar, Inc..
SEC Filings data provided by Edgar Online Inc..
Earnings data provided by FactSet CallStreet, LLC.